BRAF I Braftovi can be prescribed at the Big 5

It passed D.C. of SMC, SNUH, Seoul St. Mary's Hospital, and AMC

Insurance benefit procedures are in progress after passing the Cancer Disease Review Committee in January

Along with the progress of the insurance benefit procedure, "Braftovi," which lowers the BRAF, will be prescribed at general hospitals.

 

According to related industries, Braftovi (Encorafenib), a treatment for colorectal cancer in Ono Pharmaceutical Industry, passed the Pharmaceutical Affairs Committee (DC) of Korea University Anam Hospital, including Samsung Medical Center, Seoul National University Hospital, Seoul St.

 

Mary's Hospital, and Asan Medical Center.

 

Braftovi can be used as a combination therapy with Erbitux (Cetuximab) of Merck Korea in adult patients with direct bowel cancer with previous treatment experience and confirmed BRAF V600E mutation.

 

It is currently in the process of registering benfits, and has passed the HIRA Cancer Disease Review Committee for the first time this year in January.

 

It will be the first drug that can be prescribed for metastatic colorectal cancer with confirmed mutations in BRAF V600E with previous treatment experience.

 

Combination therapy with Braftovi was confirmed to be effective through a phase 3 clinical BEACON CRC study in patients with non-removable progressive or recurrent direct bowel cancer with BRAF V600E mutations after primary or secondary treatment.

 

In the study, combination therapy of Braftovi-Cetuximab showed statistically significant extensions (HR 0.60, p=0.0003) in the overall survival period (OS) compared to the control, Irinotecan-Cetuximab-based combination therapy.

 

The median OS value was 8.4 months in the Braftovi group and 5.4 months in the control group.

 

In the objective response rate (ORR) according to the independent central review (BICR), the combination therapy of Braftov-Cetuximab was 20%, showing a statistically significant improvement compared to 2% of the control group.

 

The median progression-free survival period (PFS) was 4.2 months for combination therapy of Braftov-Cetuximab and 1.5 months for the control group.

 

In this study, there was no unexpected toxicity of combination therapy of Braftov-Cetuximab.

 

Positive BRAF V600E gene mutation occurs in 4.7% of patients with direct bowel cancer in Korea.

 

If there is a BRAF V600E mutation, the prognosis is known to be worse than that of patients who do not.

 

There was no approved drug based on its efficacy and effectiveness in direct bowel cancer with BRAF gene mutation, so a new treatment option was needed.